The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Intravenous Dofetilide, a Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or Flutter
Open accessAbstract
OBJECTIVES: This study sought to determine the safety and efficacy of a single bolus of intravenous dofetilide, a pure class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. BACKGROUND: Dofetilide is a highly selective blocker of the rapid component of the delayed rectifier current causing action potential prolongation. These effects, and preliminary clinical data, suggest that it may be effective in the treatment of atrial fibrillation and flutter. METHODS: Ninety-one patients with sustained atrial fibrillation (75 patients) or flutter (16 patients) were entered into a double-blind, randomized multicenter study of one of two doses of dofetilide (4 or 8 micrograms/kg body weight) or placebo. RESULTS: Dofetilide effectively terminated the arrhythmia in 31% of patients receiving 8 micrograms/kg, a statistically significant difference from those receiving 4 micrograms/kg (conversion rate 12.5%, p < 0.05) or placebo (no conversion, p < 0.01). Patients with atrial flutter had a greater response to dofetilide (54% conversion rate) than those with atrial fibrillation (14.5% conversion rate, p < 0.001). CONCLUSIONS: Intravenous dofetilide can convert sustained atrial fibrillation or flutter to sinus rhythm. However, its efficacy is greater in flutter--a response that contrasts with the poorer response seen with class I agents. This finding potentially represents an important advance in the pharmacologic termination of atrial flutter.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dofetilide and ibutilide, pure class III AADs, are very effective for interrupting AFL in intravenous administration, while Class Ia and Ic drugs have little or no effect.138 -142,149”
From European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE) (2017) · cites this paper as [139]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sanguinetti, M. C., & Jurkiewicz, N. K. (1990) · The Journal of General Physiology · doi:10.1085/jgp.96.1.195 · Cited by 1,462
Coplen, S. E., Antman, E. M., Berlin, J. A., Hewitt, P., & Chalmers, T. C. (1990) · Circulation · doi:10.1161/01.cir.82.4.1106 · Cited by 946
Digoxin for Converting Recent-Onset Atrial Fibrillation to Sinus Rhythm
Falk, R. H., Knowlton, A. A., Bernard, S. A., Gotlieb, N. E., & Battinelli, N. J. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-4-503 · Cited by 335
Self-citationVoltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide.
Carmeliet, E. E. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10827-6 · Cited by 322
Capucci, A., Lenzi, T., Boriani, G., Trisolino, G., Binetti, N., Cavazza, M., Fontana, G. A., & Magnani, B. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91392-h · Cited by 227
Levine, J. H., SPEAR, J. F., Guarnieri, T., Weisfeldt, M. L., LANGEN, C. D. D., Becker, L. C., & Moore, E. N. (1985) · Circulation · doi:10.1161/01.cir.72.5.1092 · Cited by 205
Gwilt, M., Arrowsmith, J. E., Blackburn, K. J., Burges, R. A., Cross, P. E., Dalrymple, H. W., & Higgins, A. J. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23172-x · Cited by 187
Tande, P. M., Bjørnstad, H., Yang, T., & Refsum, H. (1990) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199009000-00008 · Cited by 177
Validation of double-spike electrograms as markers of conduction delay or block in atrial flutter
Cosío, F. G., Arribas, F., Barbero, J. M., Kallmeyer, C., & Goicolea, A. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)91065-x · Cited by 155
Sotalol, hypokalaemia, syncope, and torsade de pointes.
McKibbin, J. K., Pocock, W. A., Barlow, J. B., Millar, R. N. S., & Obel, I. W. P. (1984) · Heart · doi:10.1136/hrt.51.2.157 · Cited by 150
Research works printed but not linked: 3
- Bashir, 1992, Efficacy and safety of dofetilide, a new class III antiarrhythmic agent in recurrent ventricular tachycardia [abstract], Br Heart J, 68, 116
- Brachman, 1992, The efficacy and safety of oral dofetilide in patients with sustained ventricular tachycardia [abstract], Circulation, 86 Suppl I, I-265
- Hohnloser, 1992, Incidence, type and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF [abstract], PACE, 15, 551
Cited by
Sorted by citations
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Metadata
- Authors
- Falk, R. H., Pollak, A., Singh, S. N., & Friedrich, T.
- Affiliations
- Boston Medical Center (US)
- Corresponding author
- Falk, Rodney H.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 1997-02
- Volume
- 29
- Issue
- 2
- Pages
- 385-390
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2003632755
- Cited by
- 215
- References
- 30
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 4 · 2018: 2 · 2017: 2 · 2016: 7 · 2015: 4 · 2013: 4 · 2012: 5
- FWCI
- 15.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- dofetilide, intravenous administration, class III antiarrhythmic agents, sustained atrial fibrillation, atrial flutter, conversion to sinus rhythm, action potential prolongation
- MeSH terms
- Anti-Arrhythmia Agents, Atrial Fibrillation, Atrial Flutter, Double-Blind Method, Hemodynamics, Humans, Phenethylamines, Sulfonamides, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
